<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Hematol Oncol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Hematol Oncol</journal-id>
      <journal-title-group>
        <journal-title>Journal of Hematology &amp; Oncology</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1756-8722</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24669761</article-id>
      <article-id pub-id-type="pmc">3994268</article-id>
      <article-id pub-id-type="publisher-id">1756-8722-7-26</article-id>
      <article-id pub-id-type="doi">10.1186/1756-8722-7-26</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Discovery of imatinib-responsive <italic>FIP1L1-PDGFRA</italic> mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="A1">
          <name>
            <surname>Shah</surname>
            <given-names>Shilpan</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>sshah5@mdanderson.org</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Loghavi</surname>
            <given-names>Sanam</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>SLoghavi@mdanderson.org</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Garcia-Manero</surname>
            <given-names>Guillermo</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>ggarciam@mdanderson.org</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A4">
          <name>
            <surname>Khoury</surname>
            <given-names>Joseph D</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>jkhoury@mdanderson.org</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, MS-72, 77030 Houston, TX, USA</aff>
      <aff id="I2"><label>2</label>Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, MS-72, 77030 Houston, TX, USA</aff>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>27</day>
        <month>3</month>
        <year>2014</year>
      </pub-date>
      <volume>7</volume>
      <fpage>26</fpage>
      <lpage>26</lpage>
      <history>
        <date date-type="received">
          <day>24</day>
          <month>2</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>3</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2014 Shah et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2014</copyright-year>
        <copyright-holder>Shah et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.jhoonline.org/content/7/1/26"/>
      <abstract>
        <p>The <italic>FIP1L1-PDGFRA</italic> rearrangement results in constitutive activation of the tyrosine kinase PDGFRA. Neoplasms harboring this rearrangement are responsive to imatinib mesylate at doses much lower than those recommended for the treatment of chronic myelogenous leukemia. Only a single report has described the identification of <italic>FIP1L1-PDGFRA</italic> in chronic myelomonocytic leukemia (CMML). Herein, we present a case report of a patient in whom the <italic>FIP1L1-PDGFRA</italic> was discovered as he evolved from CMML to acute myeloid leukemia (AML). The presence of a dominant neoplastic clone with <italic>FIP1L1-PDGFRA</italic> rearrangement was suspected on the basis of sudden onset of peripheral and bone marrow eosinophilia and confirmed by fluorescence in situ hybridization and molecular diagnostic tests. Whereas the patient was initially refractory to chemotherapy before the rearrangement was detected, subsequent therapy with imatinib led to complete remission.</p>
      </abstract>
      <kwd-group>
        <kwd>
          <italic>FIP1L1-PDGRFA</italic>
        </kwd>
        <kwd>Chronic myelomonocytic leukemia</kwd>
        <kwd>Imatinib mesylate</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>Hypereosinophilia is a feature of a variety of uncommon hematologic disorders like hyperseosinophilic syndrome (HES), systemic mastocytosis (SM) and chronic eosinophilic leukemia (CEL). Approximately 4% of patients with HES or SM have interstitial deletion of chromosome 4q12 leading to juxtaposition of <italic>FIP1L1</italic> and <italic>PDGFRA</italic>[<xref ref-type="bibr" rid="B1">1</xref>]. The fusion product is exquisitely sensitive to therapy with imatinib mesylate, and hence its identification has important therapeutic ramifications particularly in hematologic disorders presenting with hypereosinophilia [<xref ref-type="bibr" rid="B2">2</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. We herein present the case of a patient in whom <italic>FIP1L1-PDGFRA</italic> was discovered at the time of evolution from chronic myelomonocytic leukemia (CMML) to refractory acute myeloid leukemia and how therapy with imatinib resulted in durable complete remission.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>A 64-year-old Caucasian man presented to our institution with a 6-month history of progressive leukocytosis. Per the patient&#x2019;s outside medical records, a bone marrow biopsy at initial presentation had shown a 100% cellular marrow with marked myeloid hyperplasia. Conventional cytogenetics demonstrated a diploid male karyotype. Fluorescence in situ hybridization studies (FISH) were negative for myelodysplasia-associated abnormalities. Molecular studies were negative for <italic>BCR-ABL</italic> rearrangement, and <italic>JAK2</italic><sup><italic>V617F</italic></sup> and <italic>MPL</italic><sup><italic>W515L</italic></sup> mutations. Based on these features, he was diagnosed with myelodysplastic/myeloproliferative neoplasm, unclassifiable, and was started on hydroxyurea, 1.5 grams daily. At presentation to our institution, his white blood cell (WBC) count was 44.6 &#xD7;10<sup>9</sup>/L with 76% neutrophils, 6% metamyelocytes, 10% monocytes, 6% lymphocytes, 1% eosinophils and 1% blasts, with absolute monocytosis (4.46 &#xD7; 10<sup>9</sup>/L) and eosinophilia (0.45 &#xD7; 10<sup>9</sup>/L). He was anemic (hemoglobin 9.0&#xA0;g/dL) and mildly thrombocytopenic (platelet count 119 &#xD7; 10<sup>9</sup>/L). He did not have splenomegaly on physical examination. Bone marrow evaluation performed at presentation to our institution revealed a 100% cellular bone marrow with myeloid hyperplasia. Megakaryocytes were decreased in number and included rare dysplastic forms. Wright-Giemsa stained smears prepared from the bone marrow aspirate were remarkable for increased myeloid cells and trilineage dysplasia; a 500-cell differential count showed mildly increased monocytes (6%) and myeloid blasts (7%). The constellation of findings was diagnostic of chronic myelomonocytic leukemia (CMML-1). Conventional cytogenetics showed trisomy 8 in two of twenty analyzed metaphases; this was confirmed by fluorescence in situ hybridization (FISH) using an alpha-satellite (D8Z2) CEP8 probe (positive in 4% of the cells studied). Reverse transcriptase polymerase chain reaction (RT-PCR) performed on the bone marrow aspirate was negative for <italic>BCR-ABL</italic> fusion. Targeted next-generation sequencing mutation analysis was negative for 53 &#x201C;hotspot&#x201D; mutations analyzed as described previously [<xref ref-type="bibr" rid="B6">6</xref>].</p>
      <p>The patient was enrolled on the SGI-110 clinical trial, a phase 1&#x2013;2 dose escalation, multicenter study of SGI-110, a DNA hypomethylating agent, in subjects with intermediate or high-risk myelodysplastic syndromes (MDS) or AML. He received two courses of SGI-110, after which he experienced rapidly progressive leukocytosis with a peak WBC count of 126 &#xD7; 10<sup>9</sup>/L and new onset of peripheral eosinophilia (11%). Bone marrow evaluation performed at this time demonstrated nearly 100% cellularity with myeloid hyperplasia; in contrast to the previous biopsy, prominent eosinophilia and moderate myelofibrosis were noted in this sample (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>a-b). Wright-Giemsa stained smears showed increased granulocytes with left-shifted maturation and prominent eosinophilia (16%) in a background of trilineage dysplasia. There was no significant increase in bone marrow monocytes (5%). Myeloid blasts comprised 12% of total nucleated cells. The unexpected and abrupt presence of prominent eosinophilia in the peripheral blood and bone marrow at this point in time prompted us to evaluate for <italic>PDGFRA</italic> rearrangement. FISH analysis performed using a LSI-4q12 tricolor rearrangement probe that hybridizes to the chromosome 4q12 region containing the <italic>FIP1L1</italic>, <italic>CHIC2</italic> and <italic>PDGFRA</italic> genes revealed deletion of the <italic>CHIC2</italic> gene in 86.5% of the cells analyzed indicating the presence of the <italic>FIP1L1-PDGFRA</italic> rearrangement. The <italic>FIP1L1-PDGFRA</italic> fusion transcript was further confirmed by RT-PCR. Low-level trisomy 8 was also detected by FISH in this sample. Based on these findings a diagnosis of myelodysplastic/myeloproliferative neoplasm with eosinophilia and <italic>PDGFRA</italic> rearrangement was rendered. A follow-up bone marrow biopsy after one month showed acute myeloid leukemia with 26% blasts. In addition to persistent low-level trisomy 8, conventional cytogenetics and FISH demonstrated a new clone with <italic>TP53</italic> gene deletion. FISH was positive for deletion of the <italic>CHIC2</italic> gene, <italic>TP53</italic> deletion and trisomy 8 in 90%, 10% and 9% of the analyzed cells, respectively.</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>Bone marrow core biopsy at the time of initial </bold><bold><italic>FIP1L1- PDGFRA </italic></bold><bold>rearrangement discovery.</bold> The bone marrow is hypercellular (100%), with prominent eosinophilia and myeloid hyperplasia, mild increase in immature cells, and features of myelofibrosis manifesting primarily as cellular streaming. (<bold>a</bold>: 10&#xD7; objective; <bold>b</bold>: 20&#xD7; objective; hematoxylin and eosin stain).</p>
        </caption>
        <graphic xlink:href="1756-8722-7-26-1"/>
      </fig>
      <p>The patient was then started on imatinib mesylate 400&#xA0;mg daily along with a short course of idarubucin and subcutaneous cytarabine for cytoreduction. He achieved complete hematologic and morphologic remission and went on to receive a matched unrelated allogeneic stem cell transplant (SCT). To date, the patient remains in complete hematologic, morphologic and molecular remission with successful engraftment as demonstrated by chimerism studies. The sequence of events is provided in Table&#xA0;<xref ref-type="table" rid="T1">1</xref>.</p>
      <table-wrap position="float" id="T1">
        <label>Table 1</label>
        <caption>
          <p>Sequence of clinical events</p>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
          </colgroup>
          <thead valign="top">
            <tr>
              <th align="left">
                <bold>Event sequence</bold>
              </th>
              <th align="left">
                <bold>WBC (&#xD7;10</bold>
                <sup>
<bold>9</bold>
</sup>
                <bold>)</bold>
              </th>
              <th align="left">
                <bold>Eosinophils in PB (%, AEC)</bold>
              </th>
              <th align="left">
                <bold>Eosinophils in BM (%)</bold>
              </th>
              <th align="left">
                <bold>Blasts in BM (%)</bold>
              </th>
              <th align="left">
                <bold>Diagnosis</bold>
              </th>
              <th align="left">
                <bold>Intervention</bold>
              </th>
              <th align="left">
                <bold>Disease status</bold>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="bottom">Initial presentation<hr/></td>
              <td align="left" valign="bottom">44.6<hr/></td>
              <td align="left" valign="bottom">1, 0.45<hr/></td>
              <td align="left" valign="bottom">1<hr/></td>
              <td align="left" valign="bottom">7<hr/></td>
              <td align="left" valign="bottom">CMML-1<hr/></td>
              <td align="left" valign="bottom">SGI-110<hr/></td>
              <td align="left" valign="bottom">Refractory<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">After 2&#xA0;months<hr/></td>
              <td align="left" valign="bottom">65.1<hr/></td>
              <td align="left" valign="bottom">9, 5.8<hr/></td>
              <td align="left" valign="bottom">5<hr/></td>
              <td align="left" valign="bottom">4<hr/></td>
              <td align="left" valign="bottom">CMML-1<hr/></td>
              <td align="left" valign="bottom">SGI-110<hr/></td>
              <td align="left" valign="bottom">Progression<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">After 1&#xA0;month<hr/></td>
              <td align="left" valign="bottom">126<hr/></td>
              <td align="left" valign="bottom">11, 13.8<hr/></td>
              <td align="left" valign="bottom">16<hr/></td>
              <td align="left" valign="bottom">12<hr/></td>
              <td align="left" valign="bottom">Myelodysplastic/myeloproliferative neoplasm with eosinophilia, and <italic>PDGFRA</italic> rearrangement<hr/></td>
              <td align="left" valign="bottom">Fludarabine&#x2009;+&#x2009;Cytarabine<hr/></td>
              <td align="left" valign="bottom">Progression<hr/></td>
            </tr>
            <tr>
              <td align="left">After 1&#xA0;month</td>
              <td align="left">6.4</td>
              <td align="left">1, 0.06</td>
              <td align="left">1</td>
              <td align="left">26</td>
              <td align="left">AML with <italic>PDGFRA</italic> rearrangement</td>
              <td align="left">Imatinib (with Idarubicin&#x2009;+&#x2009;Cutarabine)</td>
              <td align="left">Remission</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>WBC: white blood cells, PB: peripheral blood, AEC: absolute eosinophil count, BM: bone marrow, CMML: chronic myelomonocytic leukemia, AML: acute myeloid leukemia.</p>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>The PDGFRA and PDGFRB proteins are members of the class III receptor kinase family that also includes c-KIT, and FLT3 [<xref ref-type="bibr" rid="B7">7</xref>]. <italic>PDGFRA</italic> is located on chromosome 4q12 [<xref ref-type="bibr" rid="B8">8</xref>]. A small interstitial deletion of 4q12 leads to juxtaposition of <italic>FIP1L1</italic> and <italic>PDGFRA</italic> resulting in a gain of function fusion protein with signal independent kinase activity and therefore increased cell proliferation and survival [<xref ref-type="bibr" rid="B9">9</xref>]. This interstitial deletion is generally cryptic and not detectable using standard cytogenetic banding techniques.</p>
      <p><italic>FIP1L1- PDGFRA</italic> rearrangements are often associated with chronic eosinophilic leukemia and hypereosinophilic syndromes [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>] as well as systemic mastocytosis [<xref ref-type="bibr" rid="B11">11</xref>]. Pardanani <italic>et al.</italic> reported a prevalence of approximately 4% for <italic>FIP1L1- PDGFRA</italic> fusion gene in a large series of patients with suspected or established HES or systemic mastocysosis [<xref ref-type="bibr" rid="B1">1</xref>]. We recently described a case of chronic neutrophilic leukemia associated with <italic>FIP1L1- PDGFRA</italic> rearrangement [<xref ref-type="bibr" rid="B4">4</xref>]. The basis for the apparent lineage predilection of <italic>FIP1L1- PDGFRA</italic> for eosinophils is not well understood. The hypothesis is that it is present in all myeloid lineages, but that eosinophils are particularly sensitive to the <italic>FIP1L1- PDGFRA</italic> proliferative signal [<xref ref-type="bibr" rid="B12">12</xref>]. In contrast to rearrangements involving <italic>PDGFRB,</italic> the <italic>FIP1L1- PDGFRA</italic> rearrangement is exceedingly rare in the setting of chronic myelomonocytic leukemia [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B16">16</xref>]. To our knowledge, only one other case has been reported in the literature by Zota <italic>et al</italic>. [<xref ref-type="bibr" rid="B17">17</xref>] In contrast to our patient, the patient reported by Zota <italic>et al.</italic> did not evolve in to acute myeloid leukemia, albeit the acquisition of <italic>FIP1L1- PDGFRA</italic> fusion was considered a feature of disease evolution. Initiation of imatinib resolved eosinophilia but did not effectively improve other counts, and the patient subsequently progressed to CMML-2 and developed extramedullary disease in abdominal lymph nodes; she succumbed in 10&#xA0;months. A case series from Germany described five patients with <italic>FIP1L1- PDGFRA</italic> who presented with AML and eosinophilia, but no history of antecedent myeloid malignancy was reported for any of the patients [<xref ref-type="bibr" rid="B18">18</xref>]. A summary of case reports describing <italic>PDGFRA</italic> rearrangements arising in patients with myeloid neoplasms commonly not associated with such rearrangements is provided in Table&#xA0;<xref ref-type="table" rid="T2">2</xref>. All patients received imatinib therapy and achieved at least a hematologic response. One patient got sorafenib and another got dasatinib after acquiring resistance to imatinib. Two of eight patients maintained molecular response, while two maintained hematologic response at last reported follow up. Notably, clonal acquisition of <italic>FIP1L1-PDGFRA</italic> has not been reported in the setting of acute myeloid leukemia evolving from CMML.</p>
      <table-wrap position="float" id="T2">
        <label>Table 2</label>
        <caption>
          <p>
            <bold>
<italic>PDGFRA </italic>
</bold>
            <bold>rearrangement in unusual adult myeloid neoplasms</bold>
          </p>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
          </colgroup>
          <thead valign="top">
            <tr>
              <th align="left">
                <bold>Author/journal</bold>
              </th>
              <th align="left">
                <bold>Disease</bold>
              </th>
              <th align="left">
                <bold>Treatment</bold>
              </th>
              <th align="left">
                <bold>Outcome</bold>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td align="left" valign="bottom">Tang et al., Acta Haematol 2012;128:83&#x2013;87<hr/></td>
              <td align="left" valign="bottom">Myeloproliferative neoplasm with eosinophilia<hr/></td>
              <td align="left" valign="bottom">Imatinib &#x2013; started at 400&#xA0;mg daily and maintained at 100&#xA0;mg daily<hr/></td>
              <td align="left" valign="bottom">Complete hematologic and molecular remission at 12&#xA0;months<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Papanikolaou et al., Ann Hematol. 2012 May;91(5):785-7<hr/></td>
              <td align="left" valign="bottom">Chronic eosinophilic leukemia with lytic bone lesions<hr/></td>
              <td align="left" valign="bottom">Imatinib 200&#xA0;mg daily; on progression, nilotinib 400&#xA0;mg BID<hr/></td>
              <td align="left" valign="bottom">Progressed to erythroblastoid blast crisis after 2&#xA0;years on TKI<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Sorour et al., Br J Haematol. 2009 Jul;146(2):225-7<hr/></td>
              <td align="left" valign="bottom">Acute myeloid leukemia with eosinophilia<hr/></td>
              <td align="left" valign="bottom">Imatinib with FLAG-Ida followed by matched unrelated allograft<hr/></td>
              <td align="left" valign="bottom">Relapsed with Imatinib resistance; started on Dasatinib but died 15&#xA0;months later<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Lierman et al., Leukemia. 2009 May;23(5):845-51<hr/></td>
              <td align="left" valign="bottom">Chronic eosinophilic leukemia blast crisis with Imatinib resistance<hr/></td>
              <td align="left" valign="bottom">Sorafenib 400&#xA0;mg BID<hr/></td>
              <td align="left" valign="bottom">Hematologic response without molecular response for 3&#xA0;months<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Zota et al., J Clin Oncol. 2008 Apr 20;26(12):2040-1<hr/></td>
              <td align="left" valign="bottom">Chronic myelomonocytic leukemia<hr/></td>
              <td align="left" valign="bottom">Imatinib 400&#xA0;mg BID<hr/></td>
              <td align="left" valign="bottom">Resolution of eosinophilia without other hematologic response; progressed to extramedullary disease<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Florian et al., Leuk Res. 2006 Sep;30(9):1201-5<hr/></td>
              <td align="left" valign="bottom">Systemic mastocytosis with chronic eosinophilic leukemia<hr/></td>
              <td align="left" valign="bottom">Incomplete response to hydroxyurea, corticosteroids and interferon-alpha; started on imatinib 100&#xA0;mg in 2002<hr/></td>
              <td align="left" valign="bottom">Long-term response to low-dose Imatinib (50-100&#xA0;mg) after inadequate responses to previous therapies<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Von Bubnoff et al., Leukemia. 2005 Feb;19(2):286-7<hr/></td>
              <td align="left" valign="bottom">Chronic myeloproliferative disorder with eosinophilia<hr/></td>
              <td align="left" valign="bottom">Imatinib 100-400&#xA0;mg daily<hr/></td>
              <td align="left" valign="bottom">Hematologic and symptomatic response for 6&#xA0;months; progression to myeloid blasts crisis and malignant pleural effusion<hr/></td>
            </tr>
            <tr>
              <td align="left">Saflet et al., Genes Chromosomes Cancer 2004 May;40(1):44-50</td>
              <td align="left">Atypical chronic myeloid leukemia with t(4;22) leading to formation of BCR-PDGFRA fusion gene</td>
              <td align="left">Imatinib 100&#xA0;mg daily</td>
              <td align="left">Complete hematologic response at 7-month follow up</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>Our case highlights the importance of assessing for <italic>PDGFRA</italic> rearrangement in myeloid neoplasms with <italic>de novo</italic> or subsequently acquired eosinophilia. The identification of the <italic>FIP1L1- PDGFRA</italic> fusion gene is significant since imatinib has excellent efficacy at low doses (100-400&#xA0;mg daily) in <italic>FIP1L1-PDGFRA</italic>-positive neoplasms [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B5">5</xref>]. Of note, due to the 250-fold lower IC<sub>50</sub> as compared to <italic>BCR-ABL</italic>, reports suggest that even once weekly doses of imatinib are adequate in the setting of <italic>FIP1L1-PDGFRA</italic>[<xref ref-type="bibr" rid="B3">3</xref>]. However, these responses are eventually lost due to emergence of an imatinib-resistant T614I mutation in the ATP-binding site of <italic>PDGFRA</italic>[<xref ref-type="bibr" rid="B9">9</xref>]. In our patient, the ability to induce a complete remission using imatinib at a time when the patient was unresponsive to chemotherapy induction permitted subsequent allogeneic SCT and an ensuing durable remission as of last follow up.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusion</title>
      <p>We describe a case report of a patient who transformed from CMML to AML which was refractory to standard chemotherapy. Emergence of peripheral and bone marrow hypereosinophilia during this transformation led to suspicion of presence of <italic>FIP1L1-PDGFRA</italic> rearrangement, which was confirmed by FISH and RT-PCR. Treatment with imatinib led to a complete remission and permitted allogeneic SCT therapy.</p>
    </sec>
    <sec>
      <title>Endnote</title>
      <p>The identification of new onset of eosinophilia in acute myeloid leukemia arising in a patient with chronic myelomonocytic leukemia might indicate acquisition of imatinib-responsive <italic>FIP1L1-PDGFRA</italic> rearrangement.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Granted under protocol approved by the Institutional Review Board of The University of Texas M.D. Anderson Cancer Center.</p>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>CMML: Chronic myelomonocytic leukemia; AML: Acute myeloid leukemia; HES: Hyperseosinophilic syndrome; SM: Systemic mastocytosis; CEL: Chronic eosinophilic leukemia; FISH: Fluorescence in situ hybridization studies; PCR: Polymerase chain reaction; MDS: Myelodysplastic syndromes.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare no competing interest pertaining related to this study.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>SS, GGM and JDK: conception of manuscript, chart review, and manuscript preparation; SL: chart review and manuscript preparation. All authors have read and approved the final manuscript.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Pardanani</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ketterling</surname>
            <given-names>RP</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>CY</given-names>
          </name>
          <name>
            <surname>Patnaik</surname>
            <given-names>MM</given-names>
          </name>
          <name>
            <surname>Wolanskyj</surname>
            <given-names>AP</given-names>
          </name>
          <name>
            <surname>Elliott</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Camoriano</surname>
            <given-names>JK</given-names>
          </name>
          <name>
            <surname>Butterfield</surname>
            <given-names>JH</given-names>
          </name>
          <name>
            <surname>Dewald</surname>
            <given-names>GW</given-names>
          </name>
          <name>
            <surname>Tefferi</surname>
            <given-names>A</given-names>
          </name>
          <article-title>FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature</article-title>
          <source>Leuk Res</source>
          <year>2006</year>
          <volume>30</volume>
          <issue>8</issue>
          <fpage>965</fpage>
          <lpage>70</lpage>
          <pub-id pub-id-type="doi">10.1016/j.leukres.2005.11.011</pub-id>
          <pub-id pub-id-type="pmid">16406016</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Helbig</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Stella-Holowiecka</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Grosicki</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bober</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Krawczyk</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wojnar</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Reiter</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Hochhaus</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Holowiecki</surname>
            <given-names>J</given-names>
          </name>
          <article-title>The results of imatinib therapy for patients with primary eosinophilic disorders</article-title>
          <source>Eur J Haematol</source>
          <year>2006</year>
          <volume>76</volume>
          <issue>6</issue>
          <fpage>535</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-0609.2006.00652.x</pub-id>
          <pub-id pub-id-type="pmid">16608506</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Helbig</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Stella-Ho&#x142;owiecka</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Majewski</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ca&#x142;becka</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Gajkowska</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Klimkiewicz</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Moskwa</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Grzegorczyk</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Lewandowska</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Ho&#x142;owiecki</surname>
            <given-names>J</given-names>
          </name>
          <article-title>A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients</article-title>
          <source>Br J Haematol</source>
          <year>2008</year>
          <volume>141</volume>
          <issue>2</issue>
          <fpage>200</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2141.2008.07033.x</pub-id>
          <pub-id pub-id-type="pmid">18307562</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Jain</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Khoury</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Pemmaraju</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Kollipara</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Kantarjian</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Verstovsek</surname>
            <given-names>S</given-names>
          </name>
          <article-title>Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement</article-title>
          <source>Blood</source>
          <year>2013</year>
          <volume>122</volume>
          <issue>19</issue>
          <fpage>3387</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2013-07-516500</pub-id>
          <pub-id pub-id-type="pmid">24203930</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Metzgeroth</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Walz</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Erben</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Popp</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Schmitt-Graeff</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Haferlach</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Fabarius</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Schnittger</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Grimwade</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Cross</surname>
            <given-names>NC</given-names>
          </name>
          <name>
            <surname>Hehlmann</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Hochhaus</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Reiter</surname>
            <given-names>A</given-names>
          </name>
          <article-title>Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study</article-title>
          <source>Br J Haematol</source>
          <year>2008</year>
          <volume>143</volume>
          <issue>5</issue>
          <fpage>707</fpage>
          <lpage>15</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1365-2141.2008.07294.x</pub-id>
          <pub-id pub-id-type="pmid">18950453</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Alayed</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Patel</surname>
            <given-names>KP</given-names>
          </name>
          <name>
            <surname>Konoplev</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Singh</surname>
            <given-names>RR</given-names>
          </name>
          <name>
            <surname>Routbort</surname>
            <given-names>MJ</given-names>
          </name>
          <name>
            <surname>Reddy</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Pemmaraju</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Shaikh</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Aladily</surname>
            <given-names>TN</given-names>
          </name>
          <name>
            <surname>Jain</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Luthra</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Medeiros</surname>
            <given-names>LJ</given-names>
          </name>
          <name>
            <surname>Khoury</surname>
            <given-names>JD</given-names>
          </name>
          <article-title>TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow</article-title>
          <source>Am J Hematol</source>
          <year>2013</year>
          <volume>88</volume>
          <issue>12</issue>
          <fpage>1055</fpage>
          <lpage>61</lpage>
          <pub-id pub-id-type="doi">10.1002/ajh.23567</pub-id>
          <pub-id pub-id-type="pmid">23940084</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Reilly</surname>
            <given-names>JT</given-names>
          </name>
          <article-title>Class III receptor tyrosine kinases: role in leukaemogenesis</article-title>
          <source>Br J Haematol</source>
          <year>2002</year>
          <volume>116</volume>
          <issue>4</issue>
          <fpage>744</fpage>
          <lpage>57</lpage>
          <pub-id pub-id-type="doi">10.1046/j.0007-1048.2001.03294.x</pub-id>
          <pub-id pub-id-type="pmid">11886377</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gronwald</surname>
            <given-names>RG</given-names>
          </name>
          <name>
            <surname>Adler</surname>
            <given-names>DA</given-names>
          </name>
          <name>
            <surname>Kelly</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Disteche</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Bowen-Pope</surname>
            <given-names>DF</given-names>
          </name>
          <article-title>The human PDGF receptor alpha-subunit gene maps to chromosome 4 in close proximity to c-kit</article-title>
          <source>Hum Genet</source>
          <year>1990</year>
          <volume>85</volume>
          <issue>3</issue>
          <fpage>383</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="pmid">1697560</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Cools</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>DeAngelo</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Gotlib</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Stover</surname>
            <given-names>EH</given-names>
          </name>
          <name>
            <surname>Legare</surname>
            <given-names>RD</given-names>
          </name>
          <name>
            <surname>Cortes</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Kutok</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Clark</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Galinsky</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Griffin</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Cross</surname>
            <given-names>NC</given-names>
          </name>
          <name>
            <surname>Tefferi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Malone</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Alam</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Schrier</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Schmid</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Rose</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Vandenberghe</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Verhoef</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Boogaerts</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wlodarska</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Kantarjian</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Marynen</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Coutre</surname>
            <given-names>SE</given-names>
          </name>
          <name>
            <surname>Stone</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Gilliland</surname>
            <given-names>DG</given-names>
          </name>
          <article-title>A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome</article-title>
          <source>N Engl J Med</source>
          <year>2003</year>
          <volume>348</volume>
          <issue>13</issue>
          <fpage>1201</fpage>
          <lpage>14</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa025217</pub-id>
          <pub-id pub-id-type="pmid">12660384</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Pardanani</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Brockman</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Paternoster</surname>
            <given-names>SF</given-names>
          </name>
          <name>
            <surname>Flynn</surname>
            <given-names>HC</given-names>
          </name>
          <name>
            <surname>Ketterling</surname>
            <given-names>RP</given-names>
          </name>
          <name>
            <surname>Lasho</surname>
            <given-names>TL</given-names>
          </name>
          <name>
            <surname>Ho</surname>
            <given-names>CL</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>CY</given-names>
          </name>
          <name>
            <surname>Dewald</surname>
            <given-names>GW</given-names>
          </name>
          <name>
            <surname>Tefferi</surname>
            <given-names>A</given-names>
          </name>
          <article-title>FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia</article-title>
          <source>Blood</source>
          <year>2004</year>
          <volume>104</volume>
          <issue>10</issue>
          <fpage>3038</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2004-03-0787</pub-id>
          <pub-id pub-id-type="pmid">15284118</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Pardanani</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Pardanani</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Ketterling</surname>
            <given-names>RP</given-names>
          </name>
          <name>
            <surname>Brockman</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Flynn</surname>
            <given-names>HC</given-names>
          </name>
          <name>
            <surname>Paternoster</surname>
            <given-names>SF</given-names>
          </name>
          <name>
            <surname>Shearer</surname>
            <given-names>BM</given-names>
          </name>
          <name>
            <surname>Reeder</surname>
            <given-names>TL</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>CY</given-names>
          </name>
          <name>
            <surname>Cross</surname>
            <given-names>NC</given-names>
          </name>
          <name>
            <surname>Cools</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Gilliland</surname>
            <given-names>DG</given-names>
          </name>
          <name>
            <surname>Dewald</surname>
            <given-names>GW</given-names>
          </name>
          <name>
            <surname>Tefferi</surname>
            <given-names>A</given-names>
          </name>
          <article-title>CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>102</volume>
          <issue>9</issue>
          <fpage>3093</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2003-05-1627</pub-id>
          <pub-id pub-id-type="pmid">12842979</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gotlib</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Molecular classification and pathogenesis of eosinophilic disorders: 2005 update</article-title>
          <source>Acta Haematol</source>
          <year>2005</year>
          <volume>114</volume>
          <issue>1</issue>
          <fpage>7</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="doi">10.1159/000085559</pub-id>
          <pub-id pub-id-type="pmid">15995322</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Apperley</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Gardembas</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Melo</surname>
            <given-names>JV</given-names>
          </name>
          <name>
            <surname>Russell-Jones</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Bain</surname>
            <given-names>BJ</given-names>
          </name>
          <name>
            <surname>Baxter</surname>
            <given-names>EJ</given-names>
          </name>
          <name>
            <surname>Chase</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Chessells</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Colombat</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Dearden</surname>
            <given-names>CE</given-names>
          </name>
          <name>
            <surname>Dimitrijevic</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Mahon</surname>
            <given-names>FX</given-names>
          </name>
          <name>
            <surname>Marin</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Nikolova</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Olavarria</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Silberman</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Schultheis</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Cross</surname>
            <given-names>NC</given-names>
          </name>
          <name>
            <surname>Goldman</surname>
            <given-names>JM</given-names>
          </name>
          <article-title>Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta</article-title>
          <source>N Engl J Med</source>
          <year>2002</year>
          <volume>347</volume>
          <issue>7</issue>
          <fpage>481</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa020150</pub-id>
          <pub-id pub-id-type="pmid">12181402</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>David</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Cross</surname>
            <given-names>NC</given-names>
          </name>
          <name>
            <surname>Burgstaller</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Chase</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Curtis</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Dang</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Gardembas</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Goldman</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Grand</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Hughes</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Huguet</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Lavender</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>McArthur</surname>
            <given-names>GA</given-names>
          </name>
          <name>
            <surname>Mahon</surname>
            <given-names>FX</given-names>
          </name>
          <name>
            <surname>Massimini</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Melo</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Rousselot</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Russell-Jones</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Seymour</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Stark</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Waghorn</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Nikolova</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Apperley</surname>
            <given-names>JF</given-names>
          </name>
          <article-title>Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders</article-title>
          <source>Blood</source>
          <year>2007</year>
          <volume>109</volume>
          <issue>1</issue>
          <fpage>61</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1182/blood-2006-05-024828</pub-id>
          <pub-id pub-id-type="pmid">16960151</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Drechsler</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Hildebrandt</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>K&#xFC;ndgen</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Germing</surname>
            <given-names>U</given-names>
          </name>
          <name>
            <surname>Royer-Pokora</surname>
            <given-names>B</given-names>
          </name>
          <article-title>Fusion of H4/D10S170 to PDGFRbeta in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib</article-title>
          <source>Ann Hematol</source>
          <year>2007</year>
          <volume>86</volume>
          <issue>5</issue>
          <fpage>353</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1007/s00277-006-0247-5</pub-id>
          <pub-id pub-id-type="pmid">17211520</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>La Starza</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Rosati</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Roti</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Gorello</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Bardi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Crescenzi</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Pierini</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Calabrese</surname>
            <given-names>O</given-names>
          </name>
          <name>
            <surname>Baens</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Folens</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Cools</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Marynen</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Martelli</surname>
            <given-names>MF</given-names>
          </name>
          <name>
            <surname>Mecucci</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Cuneo</surname>
            <given-names>A</given-names>
          </name>
          <article-title>A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome</article-title>
          <source>Leukemia</source>
          <year>2007</year>
          <volume>21</volume>
          <issue>4</issue>
          <fpage>830</fpage>
          <lpage>3</lpage>
          <pub-id pub-id-type="pmid">17301821</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Zota</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Miron</surname>
            <given-names>PM</given-names>
          </name>
          <name>
            <surname>Woda</surname>
            <given-names>BA</given-names>
          </name>
          <name>
            <surname>Raza</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>SA</given-names>
          </name>
          <article-title>Eosinophilia with FIP1L1-PDGFRA fusion in a patient with chronic myelomonocytic leukemia</article-title>
          <source>J Clin Oncol</source>
          <year>2008</year>
          <volume>26</volume>
          <issue>12</issue>
          <fpage>2040</fpage>
          <lpage>1</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2007.15.3841</pub-id>
          <pub-id pub-id-type="pmid">18421057</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Metzgeroth</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Walz</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Score</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Siebert</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Schnittger</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Haferlach</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Popp</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Haferlach</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Erben</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Mix</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>M&#xFC;ller</surname>
            <given-names>MC</given-names>
          </name>
          <name>
            <surname>Beneke</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>M&#xFC;ller</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Del Valle</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Aulitzky</surname>
            <given-names>WE</given-names>
          </name>
          <name>
            <surname>Wittkowsky</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Schmitz</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Schulte</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>M&#xFC;ller-Hermelink</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Hodges</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Whittaker</surname>
            <given-names>SJ</given-names>
          </name>
          <name>
            <surname>Diecker</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>D&#xF6;hner</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Schuld</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Hehlmann</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Hochhaus</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Cross</surname>
            <given-names>NC</given-names>
          </name>
          <article-title>Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma</article-title>
          <source>Leukemia</source>
          <year>2007</year>
          <volume>21</volume>
          <issue>6</issue>
          <fpage>1183</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.leu.2404662</pub-id>
          <pub-id pub-id-type="pmid">17377585</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
